INVOKANA (Janssen Pharmaceuticals, Inc.)


Welcome to the PulseAid listing for the INVOKANA drug offered from Janssen Pharmaceuticals, Inc.. This Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Janssen Pharmaceuticals, Inc.
NON-PROPRIETARY NAME: canagliflozin
SUBSTANCE NAME: CANAGLIFLOZIN
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET, FILM COATED
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2013-03-29
END MARKETING DATE: 0000-00-00


INVOKANA HUMAN PRESCRIPTION DRUG Details:

Item DescriptionINVOKANA from Janssen Pharmaceuticals, Inc.
LABELER NAME: Janssen Pharmaceuticals, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 100(mg/1)
START MARKETING DATE: 2013-03-29
END MARKETING DATE: 0000-00-00
PRODUCT ID: 50458-140_a68673e8-e33b-4978-8593-01318d94a53f
PRODUCT NDC: 50458-140
APPLICATION NUMBER: NDA204042

Other CANAGLIFLOZIN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Janssen Pharmaceuticals, Inc.INVOKANA